Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome
(aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children …

Introduction Eculizumab is effective treatment of pediatric atypical hemolytic uremic
syndrome (aHUS). However, the optimal duration of treatment is not clearly defined. The aim …

Aim Atypical haemolytic uraemic syndrome (aHUS) is a debilitating condition that can cause
significant morbidity and mortality in children if not adequately and promptly treated. This …

Background The atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic
microangiopathy associated with high morbidity and high mortality. Eculizumab, a …

Discussion Eculizumab is an excellent drug for treating aHUS, with an overall favorable risk
profile [1, 2]. However, several issues remain to be addressed with respect to life-long …

To the Editor: Eculizumab has dramatically improved both the patient and kidney survival of
subjects with atypical Hemolytic Uremic Syndrome (aHUS)[1, 2]. However, its optimal long …

Aim Recently eculizumab, a monoclonal antibody to C5, was found to improve the disease
course of atypical haemolytic uraemic syndrome (aHUS) and has been recommended as …

Introduction Studies relating to first-line, early, and long-term eculizumab treatment and
outcomes in children with atypical hemolytic uremic syndrome (aHUS) are scarce and …

Background Eculizumab has caused a revolution in the treatment and prognosis of atypical
hemolytic uremic syndrome. Early initiation of treatment is recommended to increase …

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening
thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab …